PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling

PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling

The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the gro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SCHULER, WALTER, WARMUTH, MARKUS, STEGMEIER, FRANK P
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SCHULER, WALTER
WARMUTH, MARKUS
STEGMEIER, FRANK P
description The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2011234644BB2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2011234644BB2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2011234644BB23</originalsourceid><addsrcrecordid>eNqNzLEKwjAQgOEuDqK-ww2uBZsG97YogouDzuWM1-YgTUJyFHx7O_QBnP7l498Wn8e9A_aW3ywhZRhCArEEkghlIi8QBmhLQ86B-07RhgnB4sx-BGNT8GwAjfBMqyoTGYrLCzKPHp1b5L7YDOgyHdbuiuP18uxuJcXQU45oyJP0zUudqkrV-qx126r6T_YD478_gg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling</title><source>esp@cenet</source><creator>SCHULER, WALTER ; WARMUTH, MARKUS ; STEGMEIER, FRANK P</creator><creatorcontrib>SCHULER, WALTER ; WARMUTH, MARKUS ; STEGMEIER, FRANK P</creatorcontrib><description>The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140717&amp;DB=EPODOC&amp;CC=AU&amp;NR=2011234644B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140717&amp;DB=EPODOC&amp;CC=AU&amp;NR=2011234644B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SCHULER, WALTER</creatorcontrib><creatorcontrib>WARMUTH, MARKUS</creatorcontrib><creatorcontrib>STEGMEIER, FRANK P</creatorcontrib><title>PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling</title><description>The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzLEKwjAQgOEuDqK-ww2uBZsG97YogouDzuWM1-YgTUJyFHx7O_QBnP7l498Wn8e9A_aW3ywhZRhCArEEkghlIi8QBmhLQ86B-07RhgnB4sx-BGNT8GwAjfBMqyoTGYrLCzKPHp1b5L7YDOgyHdbuiuP18uxuJcXQU45oyJP0zUudqkrV-qx126r6T_YD478_gg</recordid><startdate>20140717</startdate><enddate>20140717</enddate><creator>SCHULER, WALTER</creator><creator>WARMUTH, MARKUS</creator><creator>STEGMEIER, FRANK P</creator><scope>EVB</scope></search><sort><creationdate>20140717</creationdate><title>PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling</title><author>SCHULER, WALTER ; WARMUTH, MARKUS ; STEGMEIER, FRANK P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2011234644BB23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2014</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SCHULER, WALTER</creatorcontrib><creatorcontrib>WARMUTH, MARKUS</creatorcontrib><creatorcontrib>STEGMEIER, FRANK P</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SCHULER, WALTER</au><au>WARMUTH, MARKUS</au><au>STEGMEIER, FRANK P</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling</title><date>2014-07-17</date><risdate>2014</risdate><abstract>The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2011234644BB2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T23%3A53%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SCHULER,%20WALTER&rft.date=2014-07-17&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2011234644BB2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true